➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Merck
McKesson
Harvard Business School
Dow

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

IZBA Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Izba, and what generic alternatives are available?

Izba is a drug marketed by Novartis and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-eight patent family members in twenty-three countries.

The generic ingredient in IZBA is travoprost. There are fifteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the travoprost profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Izba

A generic version of IZBA was approved as travoprost by PAR PHARM on March 1st, 2013.

  Try it Free

Paragraph IV (Patent) Challenges for IZBA
Tradename Dosage Ingredient NDA Submissiondate
IZBA SOLUTION/DROPS;OPHTHALMIC travoprost 204822 2015-12-30

US Patents and Regulatory Information for IZBA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis IZBA travoprost SOLUTION/DROPS;OPHTHALMIC 204822-001 May 15, 2014 DISCN Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Novartis IZBA travoprost SOLUTION/DROPS;OPHTHALMIC 204822-001 May 15, 2014 DISCN Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Novartis IZBA travoprost SOLUTION/DROPS;OPHTHALMIC 204822-001 May 15, 2014 DISCN Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Novartis IZBA travoprost SOLUTION/DROPS;OPHTHALMIC 204822-001 May 15, 2014 DISCN Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for IZBA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1514548 PA2014029 Lithuania ⤷  Try it Free PRODUCT NAME: TRAVOPROSTUM; REGISTRATION NO/DATE: EU/1/01/199/001 - EU/1/01/199/002 20011129
1920764 C01920764/01 Switzerland ⤷  Try it Free PRODUCT NAME: TRAVOPROST; REGISTRATION NUMBER/DATE: SWISSMEDIC 55910 22.05.2002
1920764 1290027-0 Sweden ⤷  Try it Free PRODUCT NAME: TRAVOPROST
1920764 PA2012017,C1920764 Lithuania ⤷  Try it Free PRODUCT NAME: TRAVOPROSTUM; NAT. REGISTRATION NO/DATE: LT 02/7821/3 20020402; FIRST REGISTRATION: EU/1/01/199/001 - EU/1/01/199/002 20011127
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Merck
McKesson
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.